antibody

botF Antibody

MBS7113778

0.05 mL

160 USD

polyclonal

rabbit

nonconjugated

western blot, ELISA, enzyme immunoassay

Antibody

botF Antibody

[botF]

[Botulinum neurotoxin type F (BoNT/F) (EC 3.4.24.69) (Bontoxilysin-F) [Cleaved into: Botulinum neurotoxin F light chain; Botulinum neurotoxin F heavy chain], botF]

[Botulinum neurotoxin type F; Botulinum neurotoxin type F; Bontoxilysin-F]

[botF]

[botF; LC; HC]

Polyclonal

IgG

Rabbit

Clostridium botulinum

1274

>95%, Protein G Purified

Liquid

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

ELISA (EIA), Western Blot (WB)

WB: 1:500-1:5000

Western Blot (WB)

Immunogen: Recombinant Clostridium botulinum Botulinum neurotoxin type F protein (1-436AA)

Conjugate: Non-Conjugated. Storage Buffer: Preservative: 0.03% Proclin 300. Constituents: 50% Glycerol, 0.01M PBS, pH 7.4. Species: Clostridium botulinum. Target Names: botF

Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that catalyzes the hydrolysis of the '58-Gln- -Lys-59' bond of synaptobrevins-1 and -2.

399137

P30996.1

P30996

Botulinum neurotoxin type F: Botulinum toxin causes flaccid paralysis by inhibiting neurotransmitter (acetylcholine) release from the presynaptic membranes of nerve terminals of the eukaryotic host skeletal and autonomic nervous system, with frequent heart or respiratory failure. Precursor of botulinum neurotoxin F which may have 2 coreceptors; complex polysialylated gangliosides found on neural tissue and specific membrane-anchored proteins found in synaptic vesicles. Receptor proteins are exposed on host presynaptic cell membrane during neurotransmitter release, when the toxin heavy chain (HC) binds to them. Upon synaptic vesicle recycling the toxin is taken up via the endocytic pathway. When the pH of the toxin-containing endosome drops a structural rearrangement occurs so that the N-terminus of the HC forms pores that allows the light chain (LC) to translocate into the cytosol. Once in the cytosol the disulfide bond linking the 2 subunits is reduced and LC cleaves its target protein on synaptic vesicles, preventing their fusion with the cytoplasmic membrane and thus neurotransmitter release (). Whole toxin only has protease activity after reduction, which releases LC (PubMed:8505288). Requires complex eukaryotic host polysialogangliosides for full neurotoxicity (). It is not clear whether a synaptic vesicle protein acts as its receptor; there is evidence for and against SV2 fulfilling this function ().

0.05 mL

160 USD

0.1 mL

235